BioTrends Research Group ranked by Philadelphia 100 for the second consecutive time

For the second year in a row, BioTrends Research Group, Inc. has been ranked as one of the fastest-growing, privately-held companies in the Philadelphia region by the Philadelphia 100, a joint project of the Wharton Small Business Development Center, the Entrepreneurs' Forum of Greater Philadelphia, and the Philadelphia Business Journal.

Over the past five years, BioTrends has become an established player in the field of syndicated market research in the healthcare sector. "In spite of industry cut-backs, our business has flourished in the past two years. We believe this is due to our unique offering - high quality primary market research conducted in specialty pharmaceutical markets and shared across multiple clients which, in turn, provides a cost effective alternative to traditional single client proprietary projects," says Sharon Funk, Vice President of Market Research Services at BioTrends.

Originally focused entirely in Nephrology, BioTrends now offers syndicated reports in multiple specialties and therapeutic categories including Multiple Sclerosis, Rheumatoid Arthritis, Psoriasis, Gout/Hyperuricemia, Inflammatory Bowel Disease, and Lupus. The 2010 Publication Plan, published earlier in September 2009, includes over 50 planned publications with new categories such as Fibromyalgia, Hepatitis, Macular Degeneration and Hypertension.

"We expect 2010 to be another exciting year for BioTrends as we expand into new therapeutic and new geographic areas. We are currently in the process of identifying savvy industry professionals to join the BioTrends team in 2010 to help us capitalize on the tremendous demand for our products and services" says Jennifer Robinson, Founder and President of BioTrends.